Clinicians can use new monoclonal antibody therapies to treat high-risk patients presenting with mild to moderate COVID-19 symptoms. However, despite the promise to depress viral loads, logistical and other challenges continue to stand in the way of larger-scale use. Still, some EDs are trying the therapeutics, with promising results.
While some researchers try to learn useful information from COVID-19 case data, other scientists are working on the early stages of various clinical trials, seeking a pharmaceutical remedy to the virus.